LONDON – There's been a summer bonanza of grants for European biotechs, with awards from different sources to fund projects ranging from early stage academic collaborations to running Phase II clinical trials. Read More
Investors in Topotarget A/S got a dose of the jitters on news that its development partner, Spectrum Pharmaceuticals Inc., will delay its new drug application (NDA) filing of Topotarget's belinostat to the fourth quarter, pushing into next year the payment dates for two badly needed milestones. Read More
LONDON – GW Pharma plc delivered positive results in a UK Phase III postmarketing study of Sativex, which will provide ballast for the launch of the cannabis-based product as a treatment for spasticity caused by multiple sclerosis in national markets across Europe and the Middle East. Read More
SHANGHAI – As the probe into Glaxosmithkline plc enters a new, quieter but possibly deeper phase, the investigation has highlighted the greater oversight that drug companies can expect in the future from the most powerful regulatory bodies in the country. Read More
SHANGHAI – The announcement that China's largest pharmaceutical company will build the country's largest biotechnology research center in Wuhan is cementing the reputation of the Chinese city as a global biotech center. China National Pharmaceutical Group Corp. (Sinopharm) plans to build the center at the Wuhan National Bioindustry Base, also known as Biolake, in the city of Wuhan in Hubei Province. Read More
SHANGHAI -–The travails of Zhejiang Hangzhou Xinfu Pharma, a small Chinese biotech firm that lost money several years running, are a clear warning to investors. Read More
Shares in Bavarian Nordic A/S gained 6.6 percent on news that the European Commission had formally approved its third-generation smallpox vaccine Imvanex, based on a modified vaccinia Ankara (MVA) vector. Read More
• Scinopharm Pharmaceuticals Ltd., of Taiwan, and Sundia Meditech Co. Ltd., of Shanghai, formed a strategic alliance to seek more opportunities for collaboration on contract research and manufacturing services in mainland China. Further terms were not disclosed. Read More
